Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment

Acta Myol. 2020 Dec 1;39(4):200-206. doi: 10.36185/2532-1900-023. eCollection 2020 Dec.

Abstract

Objectives: In Duchenne muscular dystrophy, quadriceps weakness is recognized as a key factor in gait deterioration. The objective of this work was three-fold: first, to document the strength of the quadriceps in corticosteroid-naïve DMD boys; second, to measure the effect of corticosteroids on quadriceps strength; and third, to evaluate the correlation between baseline quadriceps strength and the age when starting corticosteroids with the loss of ambulation.

Methods: Quadriceps muscle strength using hand-held dynamometry was measured in 12 ambulant DMD boys who had never taken corticosteroids and during corticosteroid treatment until the loss of ambulation.

Results: Baseline quadriceps muscle strength at 6 years of age was 28% that of normal children of the same age; it decreased to 15% at 8 years and to 6% at 10 years. The increase in quadriceps muscle strength obtained after 1 year of corticosteroid treatment had a strong direct correlation with the baseline strength (R = 0.96). With corticosteroid treatment, the age of ambulation loss showed a very strong direct relationship (R = 0.92) with baseline quadriceps muscle strength but only a very weak inverse relationship (R = -0.73) with the age of starting treatment. Age of loss of ambulation was 10.3 ± 0.5 vs 19.1 ± 4.7 (P < 0.05) in children with baseline quadriceps muscle strength less than or greater than 40 N, respectively.

Conclusions: Corticosteroid-naïve DMD boys have a quantifiable severe progressive quadriceps weakness. This long-term study, for the first time, shows that both of the positive effects obtained with CS treatment, i.e. increasing quadriceps strength and delaying the loss of ambulation, have a strong and direct correlation with baseline quadriceps muscle strength. As such, hand-held dynamometry may be a useful tool in the routine physical examination and during clinical trial assessment.

Keywords: Duchenne muscular dystrophy; corticosteroid treatment; hand-held dynamometry; prolongation of walking; quadriceps muscle strength.

MeSH terms

  • Adolescent
  • Age Factors
  • Anti-Inflammatory Agents / therapeutic use
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Muscle Strength / drug effects*
  • Muscle Strength Dynamometer
  • Muscular Dystrophy, Duchenne / drug therapy
  • Muscular Dystrophy, Duchenne / physiopathology*
  • Prednisone / therapeutic use*
  • Pregnenediones / therapeutic use*
  • Quadriceps Muscle / drug effects*
  • Quadriceps Muscle / physiopathology
  • Walking
  • Young Adult

Substances

  • Anti-Inflammatory Agents
  • Glucocorticoids
  • Pregnenediones
  • deflazacort
  • Prednisone